RBC Capital Reiterates Outperform on Biohaven, Maintains $59 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Leonid Timashev has reiterated an Outperform rating for Biohaven (NYSE:BHVN) and maintained a price target of $59.
September 04, 2024 | 1:20 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has reiterated its Outperform rating for Biohaven, maintaining a price target of $59, indicating confidence in the company's performance.
The reiteration of an Outperform rating and maintenance of a $59 price target by RBC Capital suggests a positive outlook for Biohaven. This can boost investor confidence and potentially lead to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100